Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Corporate Strategy and Milestones for 2025
Summary
Praxis Precision Medicines, Inc. announced its corporate strategy and key business priorities for 2025. The company highlighted progress in its pipeline, with three blockbuster-potential assets in late-stage clinical trials, including ulixacaltamide for essential tremor, vormatrigine for common epilepsies, and relutrigine for developmental and epileptic encephalopathies. Praxis expects pivotal readouts and NDA filings in 2025 and anticipates four commercial assets by 2028. The company also reported a cash and investments balance of approximately $470 million at the end of 2024, providing a runway into 2028.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement